<DOC>
	<DOCNO>NCT01059955</DOCNO>
	<brief_summary>This initial clinical trial evaluate whether different dos iontophoresis delivery dexamethasone phosphate tolerate eyes patient non-infections , non-necrotizing scleritis . A secondary goal get preliminary information whether treatment likely effective treatment scleritis . If result favorable , trial evaluate treatment may pursue . Funding source : FDA OOPD , Eyegate Pharmaceuticals , Inc .</brief_summary>
	<brief_title>Iontophoresis Delivery Dexamethasone Phosphate Non-infectious , Non-necrotizing Anterior Scleritis , Phase 1 Dose-varying Study</brief_title>
	<detailed_description />
	<mesh_term>Scleritis</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>1 . Male female age least 18 year 2 . A diagnosis active noninfectious , nonnecrotizing anterior scleritis ( nodular diffuse acceptable ) 3 . Not plan undergo elective ocular surgery study 4 . Provide write informed consent 5 . Be able willing follow instruction , return study visit , willing comply studyrelated instruction 6 . If female childbearing potential ; submit urine sample negative pregnancy test Visit 1 ; agree use acceptable method contraception study . A woman consider childbearing potential unless surgically sterile ( hysterectomy tubal ligation ) postmenopausal ( menstrual cycle &gt; 2 year laboratory evidence postmenopausal state ) . Acceptable method contraception include : spermicide barrier , hormonal contraception , IUD , surgical sterilization partner . Complete abstinence throughout study period also acceptable . 1 . Contraindications use test article 2 . Known allergy sensitivity medication use study , include study medication component ( e.g. , corticosteroid ) 3 . For patient take systemic corticosteroid immunosuppressant , condition constitute confer likelihood systemic corticosteroid immunosuppressant would need start 56day study period 4 . For patient already take systemic corticosteroid and/or immunosuppressant , condition confer likelihood systemic corticosteroid immunosuppressant dosage would need change 56day study period 5 . Intraocular pressure high enough intraocular pressurelowering medication likely need ( â‰¥25 mmHg IOP &gt; target pressure patient glaucoma ) ; and/or two ocular antihypertensive medication ( prior IOPlowering surgery acceptable ; combination two agent Cosopt Combigan consider two medication ) 6 . Glaucoma sufficiently advance intraocular pressure spike would potentially put patient substantial risk vision loss , per clinicianinvestigator 's judgment . 7 . Cancer 8 . Subject plan undergo elective surgery study period 9 . Any active ocular infection ( bacterial , viral , fungal ) , active ocular inflammation scleritis ( i.e. , follicular conjunctivitis , iritis ) , preauricular lymphadenopathy 10 . History diagnosis ocular herpes corneal lesion suspect herpetic origin 11 . Severe eyelid ocular surface lesion impede application iontophoresis applicator 12 . Severe / serious ocular pathology medical condition may preclude study completion 13 . Any condition confer likelihood topical ophthalmic medication use baseline would need change 56day study period . 14 . History StevensJohnson Syndrome mucous membrane pemphigoid 15 . Unwilling discontinue use contact lenses duration study 16 . Any open wound / skin disease forehead iontophoresis return electrode apply 17 . Pacemakers and/or electrical sensitive support system 18 . Any significant illness condition could , investigator 's subinvestigator 's opinion , expect interfere study parameter study conduct ; put subject significant risk 19 . Be currently pregnant , nursing , plan pregnancy ; woman positive pregnancy test 20 . Participation investigational drug device study within 30 day enter study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>scleritis</keyword>
	<keyword>anterior scleritis</keyword>
	<keyword>nodular anterior scleritis</keyword>
	<keyword>diffuse anterior scleritis</keyword>
</DOC>